ICD-10 code C52: Malignant neoplasm of vagina

Key Takeaways

ICD-10 code C52 (Malignant neoplasm of vagina) is a billable ICD-10-CM diagnosis code for primary vaginal malignancies, valid for the 2026 coding year.

C52 carries a Type 1 Excludes note: carcinoma in situ of the vagina (D07.2) must never be coded simultaneously. Using both on the same claim causes automatic denial.

C52 covers only primary vaginal malignancies. Secondary or metastatic vaginal cancer uses C79.82, not C52. The ICD-9-CM predecessor was code 184.0.

Pabau’s claims management software and structured patient record tools help gynecology and women’s health practices document and submit C52 diagnoses accurately for reimbursement.

ICD-10 code C52 is a billable, specific ICD-10-CM diagnosis code that identifies a primary malignant neoplasm of the vagina. Maintained by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS) under the authority of the World Health Organization, C52 is valid for the 2026 ICD-10-CM edition and applies to all encounters where a clinician documents primary vaginal cancer as the confirmed diagnosis.

C52 sits within the Neoplasms chapter (C00-D49) of ICD-10-CM, under the subcategory C51-C58: Malignant neoplasms of female genital organs. Unlike broader category codes, C52 is a single-code category with no further subdivisions. That means coders assign C52 itself as the final, complete code for any confirmed primary vaginal malignancy, regardless of histological subtype. Squamous cell carcinoma, adenocarcinoma, vaginal melanoma, and malignant germ cell tumors of the vagina all fall under C52, provided the vagina is the primary site of origin.

Practices coding gynecologic oncology encounters should reference the claims management software features that support accurate oncology claim submission alongside structured diagnosis documentation.

Billable status and code hierarchy for C52

C52 is confirmed billable and specific for reimbursement purposes across all major payers for the 2026 ICD-10-CM cycle. Coders do not need to add additional digits. The code is complete as listed.

The code hierarchy places C52 under the block C51-C58, which also includes malignant neoplasms of the vulva (C51), cervix uteri (C53), corpus uteri (C54), uterus unspecified (C55), ovary (C56), other and unspecified female genital organs (C57), and placenta (C58). When documentation does not specify the anatomical site within the female genital tract, coders must query the treating clinician before assigning C52 or any code in this block. Specificity of documentation is the foundation of accurate oncology coding.

Gynecology and women’s health practices can reduce documentation queries by implementing structured OB/GYN EMR software that prompts clinicians to confirm anatomical site and malignancy origin at the point of care.

Excludes notes and coding restrictions for ICD-10 code C52

C52 carries one Type 1 Excludes note: carcinoma in situ of the vagina, coded as D07.2. A Type 1 Excludes note means the two codes are mutually exclusive. D07.2 must never be reported on the same claim as C52 under any circumstance.

The clinical distinction matters because carcinoma in situ (D07.2) describes pre-invasive, non-infiltrating dysplastic changes confined to the epithelium, while C52 denotes invasive primary malignancy. Billing D07.2 and C52 together signals a contradictory clinical picture to payers and triggers automatic claim denial. Coders should verify the pathology report language: “in situ” or “VAIN III” language points to D07.2; “invasive carcinoma,” “squamous cell carcinoma of vagina,” or similar language supports C52.

The second critical distinction is between primary and secondary vaginal malignancy. A cancer that originated elsewhere and spread to the vagina is coded as C79.82 (Secondary malignant neoplasm of genital organs), not C52. This distinction requires the treating physician’s documentation to explicitly state whether the vagina is the primary site. If the documentation is ambiguous, the coder must query before assigning C52. See the ICD List diagnostic code reference for the full Type 1 Excludes note and related C79 secondary codes.

Sexual health and gynecologic oncology teams using sexual health clinic software benefit from intake forms that capture primary versus secondary malignancy status, reducing the risk of miscoding on initial claims.

Related codes and ICD-10-CM C52 code hierarchy

Accurate coding of vaginal malignancies often requires selecting among several closely related codes in the C51-C58 block and adjacent chapters. The table below identifies the most commonly encountered codes alongside C52.

For a broader view of ICD-10-CM neoplasm coding hierarchies, the CDC/NCHS ICD-10-CM web tool provides searchable access to the full 2026 tabular list. Practices covering reproductive oncology can also find related code guidance for fertility-related documentation using structured fertility clinic software that supports oncology-adjacent clinical workflows.

Additional ICD-10 diagnostic code references on the Pabau blog provide context for how specific codes sit within broader ICD-10-CM chapter structures.

ICD-9-CM crosswalk: Transitioning from code 184.0 to ICD-10 code C52

Before the ICD-10-CM transition, US providers coded primary vaginal malignancy using ICD-9-CM code 184.0. The General Equivalence Mapping (GEM) crosswalk issued by CMS maps 184.0 directly to C52 with a one-to-one forward translation. No additional specificity digits were required or lost in the conversion.

Practices that still encounter legacy billing data, audits, or retrospective reviews involving pre-2015 claims should note this mapping. Comparing old denial patterns or utilization data across the ICD-9 to ICD-10 transition requires understanding that 184.0 and C52 describe the same clinical entity. The AAPC Codify ICD-10-CM lookup provides crosswalk data and historical code mapping for reference.

When reviewing legacy records or supporting coding audits, practices that use compliance management tools can flag retrospective code inconsistencies and document the mapping rationale within the patient record.

Coding accuracy starts with better documentation

Pabau helps gynecology and women's health practices capture structured clinical data, submit oncology claims with confidence, and maintain compliant patient records from the first encounter.

Book a demo

Clinical documentation requirements to support C52

Claim denials for C52 most often trace back to two documentation gaps: incomplete confirmation of primary site and missing pathological support. The ICD-10-CM Official Guidelines for Coding and Reporting require that a definitive diagnosis be documented by the treating physician before a malignancy code is assigned. The coder cannot infer C52 from imaging findings or clinical suspicion alone.

What the clinical record must contain

• Pathology report: histopathological confirmation of malignancy, with the vagina stated as the primary site
• Physician attestation: a documented diagnosis statement using terms like “invasive vaginal carcinoma,” “malignant neoplasm of vagina,” or “primary vaginal cancer”
• Staging information: FIGO staging (Stages I-IV) supports medical necessity for treatment and payer authorization, even though staging is not encoded within C52 itself
• Treatment plan: documentation of planned or ongoing treatment (surgery, radiotherapy, chemotherapy) links the diagnosis to the services billed
• Primary vs. secondary clarification: explicit language confirming vaginal origin, especially if the patient has a history of cervical, endometrial, or colorectal cancer

Practices managing gynecologic oncology encounters benefit from structured patient record management tools that organize pathology reports, staging notes, and physician attestations in a single accessible record, reducing the time spent hunting for documentation before claim submission.

FIGO staging and ICD-10 coding

FIGO staging for vaginal cancer (Stages I through IV) describes the extent of disease but does not add additional ICD-10-CM code digits to C52. Stage is documented in the clinical record and captured in cancer registries using ICD-O morphology and topography codes, not in the ICD-10-CM claim code itself. Coders should still record staging in the patient record because payers use it to evaluate medical necessity for radiation therapy, chemotherapy authorizations, and surgical claims submitted alongside C52.

Ensuring HIPAA compliance for medical offices is particularly important when handling oncology records, where sensitive diagnosis data requires strict access controls and audit trails throughout the treatment lifecycle.

Common synonyms and equivalent terms for C52

ICD-10-CM recognizes several clinical terms as equivalent to C52. Coders encountering any of the following in documentation may assign C52, provided primary vaginal origin is confirmed:

• Carcinoma of the vagina (primary)
• Squamous cell carcinoma of the vagina
• Vaginal adenocarcinoma
• Malignant germ cell neoplasm of the vagina
• Vaginal melanoma (primary)
• Sarcoma of the vagina (primary)
• Primary vaginal cancer
• Vaginal clear cell carcinoma

Terms such as “vaginal cancer, secondary,” “metastatic vaginal carcinoma,” or “vaginal involvement from cervical cancer” do not map to C52. Those presentations use C79.82 instead. When the pathology report lists a histology that suggests a primary site other than the vagina (for example, signet-ring cell carcinoma with no identified primary), the coder should consult the treating physician before defaulting to C52.

Verifying code synonyms against the WHO ICD-10 browser helps coders confirm whether a clinical term maps to the intended code before submission. Maintaining structured patient data through patient data security tools ensures synonym-linked diagnosis records remain accessible and audit-ready.

Conclusion

Vaginal cancer coding errors cluster around one avoidable mistake: applying C52 when the vagina is not the confirmed primary site, or conflating it with D07.2 carcinoma in situ. Both errors trigger denials and create audit exposure for gynecologic oncology practices.

Pabau’s structured clinical documentation and patient intake software help practices capture primary site confirmation, staging context, and pathology linkage at the point of care. This keeps C52 claims clean from submission through adjudication. To see how Pabau supports oncology documentation workflows, book a demo.

Continue your research

Need OB/GYN-specific EMR support? OB/GYN EMR software covers the clinical documentation and scheduling features gynecology practices need for oncology and routine care.

Managing oncology-adjacent coding across specialties? Related ICD-10 code guides explore how ICD-10-CM hierarchies work across clinical specialties.

Want to reduce claim errors for complex diagnoses? Claims management software helps practices organize diagnosis codes, modifiers, and documentation before submission.

Frequently Asked Questions